US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the obesity treatment field through a licensing agreement with Denmark-based Gubra A/S (CPH: GUBRA). AbbVie has secured exclusive global development and commercialization rights to GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, Gubra will receive a total upfront payment of USD 350 million and is eligible for up to USD 1.875 billion in milestone payments related to development, commercialization, and sales, as well as tiered royalties on global net sales.
Drug Profile
Amylin, a satiety hormone, has emerged as a promising therapeutic target for obesity treatment due to its role in signaling the brain to suppress appetite and reduce food intake, while also acting as an inhibitory signal to delay gastric emptying. GUB014295, a long-acting amylin analog, is an agonist that specifically activates amylin and calcitonin receptors. The drug is currently in Phase II clinical trials, showing potential for effective obesity management.-Fineline Info & Tech
Leave a Reply